Cipla Medpro partners with Serum to provide vaccines in South Africa

The partnership will not only enable affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African Government


SII manufactures a variety of vaccine classes

Cipla Ltd. has announced that its South African subsidiary Cipla Medpro (Pty) Ltd. has entered into an exclusive agreement with the world's largest vaccine manufacturer, Serum Institute of India (SII) in South Africa.

Mr Paul Miller, CEO of Cipla Medpro, South Africa said: "This agreement will enable Cipla Medpro to become a significant player in the market. With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage."

SII manufactures a variety of vaccine classes including vaccines for Polio, Diphtheria, Tetanus, BCG (Tuberculosis), Hepatitis B, Measles, Mumps and Rubella; South Africa will be participating in the majority of these portfolios.

Mr Michel Baijot, head of Vaccines, Cipla Ltd., said, "This Cipla Medpro - SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries."

The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorizations. Cipla Medpro has exclusivity and first right of refusal of the SII pipeline within South Africa.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email